To fully participate in this online program you must be registered and logged in. Read all the information presented below. When ready select the "View Program" tab above.
Claiming CE Credits
To receive CE credits, participants must review the program materials in their entirety and complete the online post examination and evaluation with a score of 80% or better.
In September 2022, Gadopiclenol injection, which is both macrocyclic (stable) and has high relaxivity properties received FDA marketing approval and may provide dosing options that can decrease gadolinium exposure, particularly in vulnerable patients.
In this accredited Expert Forum webinar, the assessment of Gadopiclenol injection in neuro, body, and pediatric MR imaging will be presented by a panel of MR imaging experts and will include commentary from Lawrence N. Tanenbaum, MD. To encourage audience participation, a live Q & A session will follow the discussion.
CE Effective Date: May 10, 2023
CE Expiration Date: May 31, 2026
Format: Self Instructional - Audio Visual with Slides
One (1) ARRT Category A CE Credit.
One (1) AHRA CRA Credit
Estimated Completion Time: 1 hour
This webinar is an educational activity sponsored by Guerbet, LLC.
This program is intended for: Radiologic Technologists, Radiology Administrators and related Imaging Professionals.
There is no cost to participate in this program.
Upon completion of this CE activity the healthcare provider should be able to:
Lawrence N. Tanenbaum, MD
VP & Chief Technology Officer
Lawrence N Tanenbaum MD, FACR is currently Vice President & Chief Technology Officer at RadNet, Inc., a leading provider of freestanding, fixed-site diagnostic imaging services in the United States, where he also serves as Medical Director for the Eastern Region. Prior to this role, Dr. Tanenbaum served as Associate Professor of Radiology and Director of MRI/CT & Outpatient / Advanced Imaging Development at the Icahn School of Medicine at Mount Sinai in New York.
Dr. Tanenbaum has authored approximately 100 scholarly and peer reviewed articles, continues to chair educational and academic meetings, and has delivered over 1500 invited lectures around the world.
This course meets all criteria and has been approved by the AHRA, The Association for Medical Imaging Management for One (1) ARRT Category A CE Credit.
This course meets all CRA renewal credit criteria and has been approved for One (1) continuing education credit in the following CRA domains: Operations Management (OM), and Asset Management (AM)
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board or other credentialing organization.
To receive CE credits for participating in this CE activity you must successfully complete the online post examination with a passing score of 80% or higher.
Online examinations return an immediate grade report. Upon receiving a passing score click Continue and complete the evaluation form. To view and print your Statement of Credit click the Print/View Certificate button displayed from within your MyAR Archives page.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
ELUCIREM™ (gadopiclenol) injection Important Safety Information
ELUCIREM™ (gadopiclenol) injection is indicated in adult and pediatric patients aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues), and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).
History of hypersensitivity reactions to ELUCIREM
In clinical trials, the most frequent adverse reactions that occurred in > 0.2% of patients who received ELUCIREM included: injection site pain, headache, nausea, injection site warmth, injection site coldness, dizziness, and localized swelling
Adverse reactions that occurred with a frequency ≤ 0.2% in patients who received 0.05 mmol/kg BW ELUCIREM included: maculopapular rash, vomiting, worsened renal impairment, feeling hot, pyrexia, oral paresthesia, dysgeusia, diarrhea, pruritus, allergic dermatitis, erythema, injection site paresthesia, Cystatin C increase, and blood creatinine increase.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see the full Prescribing Information, including the Medication Guide, for additional important safety information.